Adam Perlman is Co-Chair of the firm’s Patent Litigation practice and focuses his practice on intellectual property disputes and other complex civil litigation. He has served as lead counsel in major patent litigations in numerous district courts around the country, and has extensive experience serving as lead appellate counsel before the U.S. Court of Appeals for the Federal Circuit. He has also litigated inter partes review proceedings before the USPTO. His patent litigation practice has had a particular emphasis on representing brand-name pharmaceutical manufacturers in Hatch-Waxman litigation, and he has tried 13 Hatch-Waxman cases. Beyond Hatch-Waxman cases, his practice has involved a wide range of technologies, including pharmaceuticals, biotechnology, medical devices, computers, and financial services. He has also litigated claims of misappropriation of trade secrets in connection with a patent and licensing dispute involving antibody technology, and in a dispute between mobile phone carriers.
Adam was recognized in the 2020 edition of Benchmark Litigation as a “National Practice Area Star” and “Local Litigation Star” for Intellectual Property. In 2016 and 2017, Adam was named “Hatch-Waxman Litigator of the Year – Branded” by LMG Life Sciences. He was named a finalist for the same award in 2018. In 2018, LMG Life Sciences honored Adam and his team with the “Hatch-Waxman Impact Case of the Year” award for their work on the Eli Lilly & Co. v Dr. Reddy’s Laboratories case. In 2017, Adam was also named an "Intellectual Property Trailblazer" by The National Law Journal. In 2018 and 2016, he was nominated by Managing IP for “Outstanding IP Litigator” for the District of Columbia. He has been recognized as a "Life Science Star" by LMG Life Sciences from 2012 to 2019, and was named an "IP Star" by Managing IP from 2013 to 2019. He has been recognized in the 2014 - 2019 editions of IAM Patent 1000 - The World’s Leading Patent Practitioners and was described in the 2019 edition as “one of the finest trial counsels in the country” and “inside and outside the courtroom, he sees the entire battlefield.” He is also listed in the 2014-2019 editions of Washington, D.C. Super Lawyers under the category of Intellectual Property Litigation. Prior to turning 40, he was named one of the country’s top five intellectual property partners under 40 by Law360. He has also been recognized as a leading attorney appearing before the Federal Circuit by the 2018 edition of IAM 1000 and was listed in the 2014 edition of The Legal 500 as having a “superb reputation” in the appellate field.
Adam has spoken regarding patent litigation issues at the winter meeting of the Association of Corporate Patent Counsel, at the ACI Paragraph IV Disputes Master Symposium, at the ALI course Trial of a Patent Case, and before other industry groups.
Outside of the intellectual property area, Adam’s practice has included Securities and Exchange Commission, Department of Justice, and internal investigations relating to alleged violations of the Foreign Corrupt Practices Act involving operations in South America and Eastern Europe. He has litigated commercial disputes in a variety of substantive areas including fraud, RICO, contract, and various business torts, and has also represented newspapers, magazines, television networks, and motion picture studios in defamation and other media-related litigation.
Adam spent five years as a member of the firm’s Hiring Committee and is a current member of the Associate Evaluation Committee.
Adam was born in Washington, D.C. and grew up in the Washington suburb of Rockville, Maryland. He graduated from Tufts University, magna cum laude, and received his J.D., summa cum laude, from the University of Pennsylvania Law School, where he was Articles Editor of the University of Pennsylvania Law Review. Adam spent a year as a law clerk to Judge Marvin J. Garbis of the U.S. District Court for the District of Maryland before joining Williams & Connolly in 1998.
- Lead trial counsel for Eli Lilly and Company at three bench trials over the validity and infringement of a Lilly patent protecting its blockbuster anti-cancer drug Alimta, which has annual U.S. sales of over $1 billion
- Lead trial counsel for Bayer at bench trial over the validity of a patent protecting its highly successful anticoagulant Xarelto, which has annual U.S. sales in the billions of dollars
- Argued 10 times before the Federal Circuit since 2012, including before the en banc court in the Alice case, which addressed the question of when computer-implemented inventions should be considered ineligible for patenting because they are abstract ideas
- Lead trial counsel for Novartis-division Alcon in litigation against generic manufacturers over patents protecting Alcon’s Pazeo product
- Lead counsel for Merck in defending patent litigation brought by PDL Biopharma relating to Merck’s Keytruda product
- Lead counsel for Lilly, Daiichi Sankyo, and Ube Industries against numerous generic manufacturers in district court litigation, inter partes review proceedings, and on appeal relating to patents protecting Lilly and Daiichi Sankyo’s Effient product
- Lead counsel for Alcon in litigation and inter partes review proceedings relating to its Ilevro, Travatan Z, Vigamox, and Moxeza products
- Lead counsel for CVS defending patent litigation brought by Walgreens relating to feature of CVS’s prescription renewal app
- Lead counsel for Bayer in litigation against multiple generic companies relating to Bayer’s Nexavar, Staxyn, and Cipro OS products
- Trial counsel for researchers from the University of Pittsburgh at the trial of an inventorship dispute with scientists from the University of California in a biotech case over the invention of stem cells derived from fat tissue
- Argued before the Federal Circuit in Eli Lilly and Company v. Teva Parenteral Medicines which was the first appellate case to address divided infringement in the pharmaceutical context
- Argued before the Federal Circuit in Alcon Research v. Barr Laboratories, which addressed the enablement and written description requirements as they relate to pharmaceutical patents
- “National Practice Area Star,” Benchmark Litigation, 2020
- “Local Litigation Star,” Benchmark Litigation, 2020
- "Life Science Star," LMG Life Sciences, 2012-2019
- “Intellectual Property: Litigation (DC),” Chambers USA, 2017-2019
- "IP Star," Managing Intellectual Property, 2013-2019
- “Leading Patent Litigation Attorney,” IAM Patent 1000, 2014-2019
- “Leading Patent Litigation Attorney” in the category of Court of Appeals for the Federal Circuit, Nationwide, IAM Patent 1000, 2018-2019
- “Hatch-Waxman Impact Case of the Year: Eli Lilly & Co. v Dr. Reddy’s Laboratories,” LMG Life Sciences, 2018
- Shortlisted, "Outstanding Litigator: District of Columbia," Managing IP, 2016, 2018
- "Intellectual Property Trailblazer," The National Law Journal, 2017
- "Hatch-Waxman Litigator of the Year – Branded," LMG Life Sciences, 2016-2017
- “Rising Star in Intellectual Property,” Law360, 2012
- Selected to Super Lawyers, 2014-2019